New copd inhaler approved for use in uk | nursing times
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
A new drug and inhaler combination has received marketing authorisation as a treatment for chronic obstructive pulmonary disease. The European Medicines Agency has approved Almirall’s
aclidinium bromide inhaler (Eklira Genuair) for twice daily use as a means of relieving symptoms in adult patients with COPD. The drug component, aclidinium (Eklira), is a new type of
long-acting muscarinic antagonist therapy. It is delivered by the Genuair multi-dose dry powder inhaler. It reduced breathlessness and improved quality of life, when compared to placebo in
trials, with data showing the significant bronchodilation achieved on day one of use was still in evidence after six months of treatment. According to its manufacturer, patients treated with
the new drug also required less rescue medication than patients treated with placebo. Eklira Genuair provides relief within 30 minutes, and offers “clinically meaningful improvements in
lung function” over 12 hours following each morning and evening administration, Almirall said. The drug and inhaler will cost £28.60.